Contracts › 75N93024C00070
75N93024C00070: The Primary Goal Is the Delineation of Functional B Cell Epitopes Recognized By Potently Neutralizing or Protective Antibodies to Facilitate Future Development of Safe and Effective Vaccines and Therapeutics.
Awarded to Washington University, the by National Institutes of Health (NIH).
$5.5Mobligated
$9.1Mpotential value
15 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93024C00070 |
|---|---|
| Awardee | Washington University, the |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | MO |
| Offers received | 18 |
| Period of performance | 16 September 2024 to 15 September 2027 |
| Potential end | 15 September 2029 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record